Orforglipron is an oral, non-peptide GLP-1 receptor agonist, approved by the FDA on 1 April 2026 as Foundayo — a once-daily prescription pill dispensed through pharmacies and Lilly's direct channel. Material sold under the name by research-chemical vendors is not the approved product. This page sets the two channels side by side and does container arithmetic for the research one only. The compound is covered in the orforglipron guide.
The one research-market orforglipron sample on Peptigrity (22 Feb 2026) was labelled 6 mg and measured 6.22 mg: 6.22 ÷ 6 = 1.037, so it held 3.7% more compound than its label. A 6 mg container holds 6 mg ÷ the amount you enter; Foundayo is dosed by a prescriber under its label, and this page does not reproduce that dose.
For research-market containers only: 6 mg is the one labelled quantity on file. Foundayo, the approved pill, is dosed by a prescriber under its FDA label, and this calculator neither reproduces nor converts that. No syringe units — orforglipron is swallowed.
Orforglipron has 1 independent lab test on file at Peptigrity. Purity is not net content: a clean certificate confirms what is in a vial, not how much. See the Orforglipron lab-test records.
Orforglipron was discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018. It activates the GLP-1 receptor through the transmembrane domain, and as a small molecule it can be swallowed as a pill — which is the whole of its difference from semaglutide and tirzepatide, both peptides. It is not a peptide, and its verification chemistry is small-molecule HPLC and mass spectrometry, not peptide sequencing. The table below is what the compound page states, as last updated in August 2026.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is it? | “A once-daily, oral, non-peptide small-molecule GLP-1 receptor agonist” | Chemical identity |
| Which route? | A pill, taken at any time of day without food or water restrictions | Approved product |
| Human evidence? | Phase 3 ACHIEVE (type 2 diabetes) and ATTAIN (obesity) programmes; ATTAIN-1 showed roughly 11–12% weight loss at 72 weeks | Phase 3 (multiple RCTs) |
| Approved? | FDA-approved 1 April 2026 as Foundayo (NDA 220934) for chronic weight management | Approved prescription medicine |
| Safety? | Boxed warning for thyroid C-cell tumours, including medullary thyroid carcinoma; mainly gastrointestinal adverse effects | Phase 3 + approved label |
| A dose on Peptigrity? | “No. Peptigrity is an independent review platform, not a medical authority.” | None — declined |
The compound-specific caveat is the one the compound page calls the whole story: no legitimate supply route delivers Foundayo to research-chemical vendors, so research-market “orforglipron” is by definition not the pharmacy product, and a vendor certificate built on peptide-style HPLC purity alone is the wrong verification for a small molecule — identity needs LC-MS confirmation.
The table sets the two channels side by side as the compound page describes them (Last Updated: August 2026); the research column's test figure is from the lab record as read on 21 September 2026.
| Prescription channel — Foundayo | Research channel — “orforglipron” | |
|---|---|---|
| What it is | Eli Lilly's approved medicine, FDA-approved 1 April 2026 under NDA 220934 | Material sold under the name by research-chemical vendors — not the approved product |
| How it is supplied | Dispensed on prescription through pharmacies and Lilly's direct channel | Research-chemical vendors; no legitimate supply route delivers Foundayo to them |
| Form | A once-daily pill, with no food or water timing restrictions | Research containers; the one sample on file was labelled 6 mg |
| Indication | Chronic weight management in adults with obesity, or overweight with at least one weight-related condition | None — research use |
| Amount | Set by the prescriber under the FDA label (not reproduced on this page) | None — Peptigrity does not recommend an orforglipron dose |
| Quality chain | The approved manufacturing and quality chain | Has not been through that chain and cannot be assumed to contain what its label claims |
| Independent tests on Peptigrity | — | 1 test on file (February 2026) |
| Warnings | Boxed warning for thyroid C-cell tumours; contraindicated with a personal or family history of MTC or MEN 2 | The FDA label and its warnings were written for Foundayo; research material is not the approved product |
For anyone deciding between the two, the compound page is explicit about which one is the medicine: the approved pill comes through a prescription and a pharmacy. The trial evidence and how Foundayo compares with the injectable GLP-1 peptides are in orforglipron versus injectable GLP-1 peptides.
No syringe arithmetic, because orforglipron is swallowed — there is nothing to reconstitute and nothing to draw. No dose table, because the compound page states no dose: the approved pill's amount is a prescriber's decision under the FDA label, and for research-market material Peptigrity declines the question outright. Peptigrity's orforglipron article adds a caution that matters to any milligram figure: the Phase 3 programme used a capsule, the marketed product is a tablet, and the two are not interchangeable milligram for milligram — so a number taken from a trial report is not a tablet strength, and neither is the label on a research container.
The calculator does one division: amounts per container = label mg ÷ your amount. It offers one container size, because the only labelled research-market quantity on file is 6 mg. The table gives that one test as the compound page lists it on 21 September 2026, with the difference computed here.
| Test date | Labelled | Measured | Difference | Lab |
|---|---|---|---|---|
| 22 Feb 2026 | 6 mg | 6.22 mg | +3.7% | Ethos Analytics |
One result is one batch. It shows the sample held 3.7% more than its label; it cannot show whether other research containers hold the approved molecule at all, which is the question the compound page says matters most. This page shows no prices or cost figures for orforglipron. How to read a small-molecule certificate: reading lab test results.
Per the compound page, orforglipron is an FDA-approved prescription medicine — Foundayo, approved 1 April 2026 under NDA 220934 — for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, dispensed through pharmacies and Lilly's direct channel. It is the first non-peptide oral GLP-1 approved for obesity, but not the first oral GLP-1: oral semaglutide, a peptide formulation, was approved for obesity in December 2025. Any orforglipron sold by a research-chemical vendor is not the approved product. Country rules: regulatory status by country.
Independent test record: orforglipron lab tests. The peptide GLP-1 it is most often compared with: semaglutide.
For Foundayo, the approved prescription pill, the dose is set by a prescriber under the FDA label; this page does not reproduce it. For research-market material there is no dose: Peptigrity does not recommend an orforglipron dose, and that material is not the approved product.
No. It is an oral, non-peptide small-molecule GLP-1 receptor agonist - unlike semaglutide and tirzepatide, which are peptides. That is why it can be taken as a pill without food or water restrictions.
No. Foundayo is dispensed through pharmacies and Lilly's direct channel, and the compound page states that no legitimate supply route delivers it to research-chemical vendors. Material sold under the name has not been through the approved manufacturing and quality chain and cannot be assumed to contain what its label claims.
Because orforglipron is an approved prescription medicine, this page points to the prescription channel rather than to research-vendor prices. The compound page's fact sheet also records no price feed for it (fewer than 3 comparable in-stock listings, as of 21 September 2026).
Yes - for thyroid C-cell tumours, including medullary thyroid carcinoma. It is contraindicated in anyone with a personal or family history of MTC or multiple endocrine neoplasia type 2.